AZI2 Antibody

Basic Research Questions

• What is AZI2 and what cellular functions should researchers consider when designing experiments?

AZI2 (5-azacytidine induced 2), also known as NAP1, is a 45 kDa adapter protein that plays critical roles in multiple cellular pathways. It functions as a TNF receptor (TNFR)-associated factor family member-associated NF-κB activator-binding kinase 1-binding protein that regulates the production of interferons .

Researchers should consider:

• AZI2's role in binding TBK1 and IKBKE, which are essential for antiviral innate immunity

• Its involvement in selective autophagy and TBK1-IFN pathway activation

• Its function in bone homeostasis through regulation of osteoclast survival

• Its cytoplasmic localization (which impacts staining protocols)

When designing experiments, account for AZI2's expression in multiple cell types including HeLa, HEK-293, U2OS, MDA-MB-231, and various immune cells .

• What applications are AZI2 antibodies validated for, and how should dilution factors be optimized?

AZI2 antibodies have been validated for multiple applications:

For optimization:

• Perform serial dilutions within the recommended range

• Test with positive control samples (HEK-293, HeLa, HepG2 cells show consistent AZI2 expression)

• Include negative controls using isotype-matched control antibodies

• For each application, titrate the antibody specifically for your cell/tissue type

• How can sample preparation be optimized for AZI2 detection in different applications?

Sample preparation is critical for successful AZI2 detection:

For Western Blot:

• Use RIPA or NP-40 buffer with protease inhibitors

• Include phosphatase inhibitors when studying AZI2 phosphorylation state

• Load 20-30 μg of total protein for cell lines

• Expected molecular weight is 45 kDa (observed between 45-47 kDa)

For Immunofluorescence:

• 4% paraformaldehyde fixation (10-15 minutes)

• 0.1-0.2% Triton X-100 permeabilization (5-10 minutes)

• Block with 1-5% BSA or normal serum

• Primary antibody incubation: overnight at 4°C or 1-2 hours at room temperature

For Immunohistochemistry:

• Consider antigen retrieval with TE buffer pH 9.0 or citrate buffer pH 6.0

• Test both FFPE and frozen sections for optimal results

• Validated positive control tissues: mouse testis, human pancreas, stomach, and testis

• What positive controls should be included when using AZI2 antibodies?

Based on validation data, include appropriate positive controls:

For Western Blot:

• HEK-293 cells, HeLa cells, HepG2 cells, U2OS cells, MDA-MB-231 cells

For Immunofluorescence:

• HeLa cells, HepG2 cells have been validated for positive IF staining

For Immunohistochemistry:

• Mouse testis tissue, human pancreas tissue, human stomach tissue, human testis tissue

For tissue-specific studies:

• Mouse/rat testis for reproductive studies

• Human/mouse breast cancer cell lines (MDA-MB-231, SK-BR-3, 4T1) for cancer research

Include biological replicates and appropriate loading controls (β-actin, GAPDH) for quantitative analyses.

Advanced Research Questions

• How can researchers effectively study AZI2's role in regulating osteoclast longevity and bone homeostasis?

To investigate AZI2's function in bone homeostasis:

Experimental approach:

• Primary osteoclast cultures from wild-type vs. AZI2-deficient mice

• Analyze osteoclast differentiation markers (TRAP, cathepsin K)

• Measure osteoclast survival through apoptosis assays (Annexin V, TUNEL)

• Assess bone parameters using μCT analysis and bone histomorphometry

Key methodological considerations:

• Use AZI2 antibodies (1:1000 dilution) for Western blot to verify knockout efficiency

• Examine c-Src phosphorylation status and Hsp90-Cdc37 interaction as downstream mechanisms

• Consider c-Src inhibitors as experimental controls

• Include proper controls for compensatory mechanisms in knockout models

Analysis of results:

• Correlate osteoclast parameters with trabecular bone volume

• Evaluate both osteoclast number and activity parameters

• Consider age-dependent effects (perform analyses at multiple timepoints)

• What approaches can researchers use to study AZI2-mediated TBK1 activation in the context of autophagy?

To investigate AZI2's role in TBK1 activation and autophagy:

Experimental design:

• Utilize immunofluorescence to track AZI2 puncta formation during selective autophagy

• Compare bulk autophagy (HBSS treatment) vs. selective autophagy (e.g., FCCP-induced mitophagy)

• Implement genetic approaches (RB1CC1 knockout) to accumulate AZI2 at selective autophagy sites

• Screen for pharmacological agents (e.g., Lys05) that induce AZI2 puncta formation

Technical considerations:

• Use live-cell imaging with GFP-AZI2 constructs to monitor dynamics

• Combine with TBK1 phosphorylation (p-TBK1) analysis by Western blot

• Co-stain for selective autophagy markers (SQSTM1/p62, NBR1, OPTN)

• Implement imaging cytometry for quantitative assessment of puncta formation

Data interpretation:

• Distinguish between bulk and selective autophagy effects

• Correlate AZI2 puncta formation with TBK1 activation markers

• Analyze downstream activation of DDX3X and IRF3

• Assess pro-inflammatory chemokine expression (CXCL9, CXCL10, CCL5)

• How can researchers accurately assess AZI2's interactions with binding partners in the TBK1-IFN signaling pathway?

For studying AZI2 protein-protein interactions:

Methodological approaches:

• Co-immunoprecipitation using AZI2 antibodies (0.5-4.0 μg per mg of lysate)

• Proximity ligation assays to visualize interactions in situ

• FRET/BRET approaches for real-time interaction monitoring

• GST pull-down assays with recombinant proteins

Experimental considerations:

• Use mild lysis conditions to preserve protein complexes (NP-40 or Triton X-100 buffers)

• Include appropriate negative controls (isotype IgG, binding-deficient mutants)

• Confirm specificity with reciprocal immunoprecipitations

• Validate interactions under different stimulation conditions (e.g., viral infection, selective autophagy induction)

For TBK1 pathway analysis:

• Monitor phosphorylation of TBK1 (Ser172)

• Assess IRF3 phosphorylation and nuclear translocation

• Measure IFN-β production by ELISA or qPCR

• Evaluate interaction with DDX3X and its impact on IRF3

• What strategies can be employed to distinguish between AZI2's functions in different cellular contexts?

To differentiate AZI2's context-specific functions:

Experimental strategies:

• Tissue-specific or inducible knockout models

• Cell type-specific promoter-driven expression systems

• Domain-specific mutants to disrupt specific interactions

• Temporal control of AZI2 depletion/overexpression

For immunological studies:

• Compare dendritic cell differentiation, TLR signaling, and antigen presentation

• Assess pro-inflammatory cytokine production in response to various stimuli

• Evaluate acquired immune functions through OVA-specific IgM and IgG1 production

• Analyze T cell activation by CD11c-positive splenocytes

For bone research:

• Separate analyses of osteoclast formation vs. survival

• Examine osteoblast parameters and bone-forming rate

• Investigate c-Src and Hsp90-Cdc37 pathway involvement

• Consider using c-Src inhibitors as experimental intervention

For cancer studies:

• Assess CD8+ T cell infiltration in correlation with AZI2 expression

• Analyze pro-inflammatory chemokine expression

• Investigate selective autophagy disruption effects

• Consider combination with immune checkpoint inhibitors

• How should researchers interpret contradictory AZI2 functional data between in vitro and in vivo models?

When facing contradictions between in vitro and in vivo findings:

Analytical framework:

• Systematically compare experimental conditions (cell types, stimulation protocols)

• Consider compensatory mechanisms present in vivo but absent in vitro

• Evaluate developmental vs. acute effects in knockout models

• Assess potential cell type-specific functions

Key considerations:

• For immune function studies: dendritic cell differentiation appears normal in vivo despite in vitro defects

• For bone metabolism: osteoclast survival effects may be masked by other regulatory mechanisms

• For autophagy research: bulk vs. selective autophagy may show differential AZI2 involvement

Resolution strategies:

• Implement acute depletion approaches (e.g., inducible knockouts, degraders)

• Use tissue-specific or cell type-specific gene targeting

• Combine genetic and pharmacological approaches

• Employ rescue experiments with wild-type or mutant constructs

• Consider cross-talk between pathways that may be absent in simplified in vitro systems

• What are the methodological considerations for studying AZI2's role in breast cancer and immune checkpoint inhibitor responses?

For investigating AZI2 in cancer immunology:

Experimental design:

• Assess AZI2 expression in breast cancer tissue microarrays

• Correlate AZI2 levels with CD8+ T cell infiltration and patient outcomes

• Implement genetic (AZI2 overexpression/depletion) and pharmacological approaches

• Evaluate combination with immune checkpoint inhibitors

Technical considerations:

• Use immunohistochemistry (1:50-1:500 dilution) for patient samples

• Employ imaging cytometry to quantify AZI2 puncta formation

• Consider GFP-AZI2 sorting to isolate high vs. low expressing populations

• Monitor downstream chemokine expression by qPCR or multiplex protein assays

Data interpretation strategies:

• Correlate AZI2 expression with clinical parameters

• Assess association between AZI2 levels and relapse-free survival

• Evaluate the relationship between AZI2 expression and T cell infiltration

• Consider breast cancer subtypes in analysis (AZI2 appears consistent across subtypes)

For translational approaches:

• Screen for compounds that induce AZI2-TBK1 pathway activation

• Consider combining selective autophagy inhibitors with immunotherapies

• Develop biomarkers based on AZI2 expression patterns and subcellular localization

Experimental Protocols and Troubleshooting

• What are the optimal Western blot conditions for detecting AZI2 protein?

Recommended Western blot protocol for AZI2:

Sample preparation:

• Lyse cells in RIPA buffer with protease/phosphatase inhibitors

• Denature samples at 95°C for 5 minutes in Laemmli buffer

• Load 20-30 μg of total protein per lane

Gel electrophoresis and transfer:

• Use 10-12% SDS-PAGE gels

• Transfer to PVDF membrane (recommended over nitrocellulose)

• Wet transfer at 100V for 60-90 minutes or 30V overnight

Antibody incubation:

• Block with 5% non-fat milk or BSA in TBST (1 hour, room temperature)

• Primary antibody dilution: 1:5000-1:10000 for high sensitivity detection

• Incubate overnight at 4°C with gentle rocking

• Secondary antibody: HRP-conjugated anti-rabbit/mouse IgG at 1:5000-1:10000

Expected results:

• AZI2 band at approximately 45 kDa (observed range: 45-47 kDa)

• Validated positive controls: HEK-293, HeLa, HepG2, U2OS cells

Troubleshooting:

• Multiple bands: Try different lysis buffers or antibody batches

• Weak signal: Increase protein loading or antibody concentration

• High background: Extend blocking time or add 0.1% Tween-20 to antibody dilutions

• How can researchers optimize immunofluorescence protocols for AZI2 visualization?

Optimized immunofluorescence protocol for AZI2:

Cell preparation:

• Culture cells on glass coverslips or chamber slides

• For puncta formation studies, consider selective autophagy induction (e.g., FCCP treatment)

Fixation and permeabilization:

• Fix with 4% paraformaldehyde (15 minutes, room temperature)

• Permeabilize with 0.2% Triton X-100 (10 minutes, room temperature)

• Block with 3% BSA in PBS (1 hour, room temperature)

Antibody incubation:

• Primary antibody dilution: 1:200-1:800 in blocking buffer

• Incubate overnight at 4°C in a humidified chamber

• Secondary antibody: fluorophore-conjugated anti-rabbit/mouse IgG at 1:500

• Include DAPI for nuclear counterstaining

Imaging considerations:

• Use confocal microscopy for optimal resolution of AZI2 puncta

• For co-localization studies, include autophagy markers (SQSTM1/p62, NBR1)

• Consider live-cell imaging with GFP-AZI2 constructs for dynamic studies

Quantification methods:

• Count cells with AZI2 puncta as percentage of total cells

• Measure puncta number, size, and intensity per cell

• Use imaging cytometry for higher throughput quantification

Validated positive controls:

• HeLa cells, HepG2 cells show distinct cytoplasmic staining